By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Drugs > Selpercatinib (systemic) (monograph) > Selpercatinib Dosage
Drugs
https://themeditary.com/dosage-information/selpercatinib-dosage-15687.html

Selpercatinib Dosage

Drug Detail:Selpercatinib (systemic) (monograph) (Retevmo)

Drug Class:

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Non-Small Cell Lung Cancer

Less than 50 kg: 120 mg orally 2 times daily (approximately every 12 hours) until disease progression or unacceptable toxicity

50 kg or greater: 160 mg orally 2 times daily (approximately every 12 hours) until disease progression or unacceptable toxicity

Use: For the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)

Usual Adult Dose for Thyroid Cancer

Less than 50 kg: 120 mg orally 2 times daily (approximately every 12 hours) until disease progression or unacceptable toxicity

50 kg or greater: 160 mg orally 2 times daily (approximately every 12 hours) until disease progression or unacceptable toxicity

Uses:

  • For the treatment of adult patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
  • For the treatment of adult patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)

Usual Pediatric Dose for Thyroid Cancer

12 years and older:
Less than 50 kg: 120 mg orally 2 times daily (approximately every 12 hours) until disease progression or unacceptable toxicity

12 years and older:
50 kg or greater: 160 mg orally 2 times daily (approximately every 12 hours) until disease progression or unacceptable toxicity

Uses:

  • For the treatment of pediatric patients 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy
  • For the treatment of pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)

Renal Dose Adjustments

Mild to moderate renal impairment (CrCl greater than 30 mL/min): No adjustment recommended.
Severe renal impairment (CrCl less than 30 mL/min or end-stage renal disease): Data not available

Liver Dose Adjustments

Mild (total bilirubin less than or equal to ULN with AST greater than upper limit of normal [ULN] or total bilirubin greater than 1 to 1.5 times ULN with any AST) or moderate (total bilirubin greater than 1.5 to 3 x ULN and any AST): No adjustment recommended.
Severe (total bilirubin greater than 3 to 10 x ULN and any AST) hepatic impairment:

  • Current dose of this drug is 120 mg orally 2 times daily: Reduce dose to 80 mg orally 2 times daily.
  • Current dose of this drug is 160 mg orally 2 times daily: Reduce dose to 80 mg orally 2 times daily.

Dose Adjustments

RECOMMENDED DOSE REDUCTIONS FOR ADVERSE REACTIONS:
First dose reduction:

  • Less than 50 kg: 80 mg orally 2 times daily
  • Fifty (50) kg or greater: 120 mg orally 2 times daily
Second dose reduction:
  • Less than 50 kg: 40 mg orally 2 times daily
  • Fifty (50) kg or greater: 80 mg orally 2 times daily
Third dose reduction:
  • Less than 50 kg: 40 mg orally 2 times daily
  • Fifty (50) kg or greater: 40 mg orally 2 times daily
NOTE: Permanently discontinue this drug in patients unable to tolerate 3 dose reductions.

RECOMMENDED DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
HEPATOTOXICITY:
  • Grade 3 or 4: Withhold therapy and monitor AST/ALT once weekly until resolution to Grade 1 or baseline.
  • Resume therapy at reduced dose by 2 dose levels and monitor AST and ALT once weekly until 4 weeks after reaching dose taken prior to the onset of Grade 3 or 4 increased AST or ALT.
  • Increase dose by 1 dose level after a minimum of 2 weeks without recurrence and then increase to dose taken prior to the onset of Grade 3 or 4 increased AST or ALT after a minimum of 4 weeks without recurrence.
HYPERTENSION:
  • Grade 3: Withhold therapy for Grade 3 hypertension that persists despite optimal antihypertensive therapy; resume at a reduced dose when hypertension is controlled.
  • Grade 4: Discontinue this drug.
OT INTERVAL PROLONGATION:
  • Grade 3: Withhold therapy until recovery to baseline or Grade 0 or 1; resume at a reduced dose.
  • Grade 4: Discontinue this drug.
HEMORRHAGIC EVENTS:
  • Grade 3 or 4: Withhold therapy until recovery to baseline or Grade 0 or 1; discontinue therapy for severe or life-threatening hemorrhagic events.
HYPERSENSITIVITY REACTIONS:
  • All grades: Withhold therapy until resolution of the event; initiate corticosteroids; resume at a reduced dose by 3 dose levels while continuing corticosteroids; increase dose by 1 dose level each week until the dose taken prior to the onset of hypersensitivity is reached, then taper corticosteroids.
OTHER ADVERSE REACTIONS:
  • Grade 3 or 4: Withhold therapy until recovery to baseline or Grade 0 or 1; resume therapy at a reduced dose.

RECOMMENDED DOSE MODIFICATIONS FOR CONCOMITANT USE OF STRONG AND MODERATE CYP450 3A INHIBITORS:
  • Avoid concomitant use of strong and moderate CYP450 3A inhibitors with this drug.
  • If concomitant use of a strong or moderate CYP450 3A inhibitor cannot be avoided, reduce the dose of this drug as recommended.
  • After the inhibitor has been discontinued for 3 to 5 elimination half-lives, resume this drug at the dose taken prior to initiating the CYP450 3A inhibitor.
CURRENT SELPERCATINIB DOSE 120 MG ORALLY 2 TIMES DAILY:
  • Moderate CYP450 3A inhibitor: Reduce dose to 80 mg orally 2 times daily.
  • Strong CYP450 3A inhibitor: Reduce dose to 40 mg orally 2 times daily.
CURRENT SELPERCATINIB DOSE 160 MG ORALLY 2 TIMES DAILY:
  • Moderate CYP450 3A inhibitor: Reduce dose to 120 mg orally 2 times daily.
  • Strong CYP450 3A inhibitor: Reduce dose to 80 mg orally 2 times daily.

Precautions

CONTRAINDICATIONS:

  • None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • This drug may be taken with or without food unless coadministered with a proton pump inhibitor (PPI); take with food if given with a PPI, a histamine-2 (H2) receptor antagonist, or a locally acting antacid. If concomitant use cannot be avoided, take this drug with food when coadministered with a PPI.
  • Take this drug 2 hours before or 10 hours after administration of an H2 receptor antagonist.
  • Take this drug 2 hours before or 2 hours after administration of a locally acting antacid.
  • Swallow the capsules whole; do not crush or chew the capsules.
  • Do not take a missed dose unless it is more than 6 hours until next scheduled dose.
  • If vomiting occurs after administration, do not take an additional dose and continue to the next scheduled time for the next dose.

Storage requirements:
  • Store at 20C to 25C (68F to 77F); excursions between 15C and 30C (59F to 86F) are permitted.

Monitoring:
  • Hepatic function
  • Cardiac function
Share this Article
Latest News
Medical News

Obesity, unhealthy lifestyles may cause heart to age by 5–45 years

May 08, 2025
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Heart disease: Just 3 minutes of 'incidental activity' may lower...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by